These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 29440449)

  • 1. Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks.
    Su SP; Flashner-Abramson E; Klein S; Gal M; Lee RS; Wu J; Levitzki A; Daly RJ
    Mol Cancer Ther; 2018 May; 17(5):931-942. PubMed ID: 29440449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NT157 exerts antineoplastic activity by targeting JNK and AXL signaling in lung cancer cells.
    de Miranda LBL; Lima K; Coelho-Silva JL; Traina F; Kobayashi SS; Machado-Neto JA
    Sci Rep; 2022 Oct; 12(1):17092. PubMed ID: 36224313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin Receptor Substrate Suppression by the Tyrphostin NT157 Inhibits Responses to Insulin-Like Growth Factor-I and Insulin in Breast Cancer Cells.
    Yang Y; Chan JY; Temiz NA; Yee D
    Horm Cancer; 2018 Dec; 9(6):371-382. PubMed ID: 30229539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.
    Flashner-Abramson E; Klein S; Mullin G; Shoshan E; Song R; Shir A; Langut Y; Bar-Eli M; Reuveni H; Levitzki A
    Oncogene; 2016 May; 35(20):2675-80. PubMed ID: 26119932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IGF1R/IRS1 targeting has cytotoxic activity and inhibits PI3K/AKT/mTOR and MAPK signaling in acute lymphoblastic leukemia cells.
    Rodrigues Alves APN; Fernandes JC; Fenerich BA; Coelho-Silva JL; Scheucher PS; Simões BP; Rego EM; Ridley AJ; Machado-Neto JA; Traina F
    Cancer Lett; 2019 Aug; 456():59-68. PubMed ID: 31042587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NT157 Inhibits HCC Migration via Downregulating the STAT3/Jab1 Signaling Pathway.
    Yu S; Wang Y; Lv K; Hou J; Li W; Wang X; Guo H; Wang W
    Technol Cancer Res Treat; 2021; 20():15330338211027916. PubMed ID: 34238066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NT157 has antineoplastic effects and inhibits IRS1/2 and STAT3/5 in JAK2
    Fenerich BA; Fernandes JC; Rodrigues Alves APN; Coelho-Silva JL; Scopim-Ribeiro R; Scheucher PS; Eide CA; Tognon CE; Druker BJ; Rego EM; Machado-Neto JA; Traina F
    Signal Transduct Target Ther; 2020 Jan; 5(1):5. PubMed ID: 32296029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NT157 inhibits cell proliferation and sensitizes glioma cells to TRAIL-induced apoptosis by up-regulating DR5 expression.
    Hou YJ; Li D; Wang W; Mao L; Fu X; Sun B; Fan C
    Biomed Pharmacother; 2022 Sep; 153():113502. PubMed ID: 36076591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.
    Ibuki N; Ghaffari M; Reuveni H; Pandey M; Fazli L; Azuma H; Gleave ME; Levitzki A; Cox ME
    Mol Cancer Ther; 2014 Dec; 13(12):2827-39. PubMed ID: 25267499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting tumor-stroma crosstalk: the example of the NT157 inhibitor.
    Rampias T; Favicchio R; Stebbing J; Giamas G
    Oncogene; 2016 May; 35(20):2562-4. PubMed ID: 26477311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells.
    Badache A; Hynes NE
    Cancer Res; 2001 Jan; 61(1):383-91. PubMed ID: 11196191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer.
    Kim JY; Welsh EA; Fang B; Bai Y; Kinose F; Eschrich SA; Koomen JM; Haura EB
    Mol Cancer Res; 2016 Oct; 14(10):1019-1029. PubMed ID: 27422710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Global phosphoproteomic effects of natural tyrosine kinase inhibitor, genistein, on signaling pathways.
    Yan GR; Xiao CL; He GW; Yin XF; Chen NP; Cao Y; He QY
    Proteomics; 2010 Mar; 10(5):976-86. PubMed ID: 20049867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Effectiveness of Selective Inhibitor of IRS-1/2 NT157 in Osteosarcoma Cell Lines.
    Garofalo C; Capristo M; Mancarella C; Reunevi H; Picci P; Scotlandi K
    Front Endocrinol (Lausanne); 2015; 6():74. PubMed ID: 26029165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia increases the heterogeneity of melanoma cell populations and affects the response to vemurafenib.
    Pucciarelli D; Lengger N; Takáčová M; Csaderova L; Bartosova M; Breiteneder H; Pastorekova S; Hafner C
    Mol Med Rep; 2016 Apr; 13(4):3281-8. PubMed ID: 26936534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor-alpha induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway.
    Li G; Barrett EJ; Barrett MO; Cao W; Liu Z
    Endocrinology; 2007 Jul; 148(7):3356-63. PubMed ID: 17446186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of non-receptor and receptor tyrosine kinases (TKs) in the antitumor action of alpha-difluoromethylornithine (DFMO) in breast cancer cells.
    Xu H; Washington S; Verderame MF; Manni A
    Breast Cancer Res Treat; 2008 Nov; 112(2):255-61. PubMed ID: 18097746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin signaling leading to proliferation, survival, and membrane ruffling in C2C12 myoblasts.
    Conejo R; Lorenzo M
    J Cell Physiol; 2001 Apr; 187(1):96-108. PubMed ID: 11241354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.